This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.


Generic Name
Placental Mesenchymal Stem Cells
DrugBank Accession Number

The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are obtained from either the fetal side, which hold chorionic plate-derived MSCs, or the maternal side, which contributes decidual parietalis-dreived MSCs. Although pMSCs have multi-lineage differentiation potential, the fetal-side pMSCs have greater expansion capacity, proliferation and differentiation potential than maternal-side pMSCs. It was also found that fetal-side pMSCs express different surface markers.

Biologic Classification
Cell transplant therapies
Other cell transplant therapies
  • Placental mesenchymal stromal cells
External IDs
  • Placental Mesenchymal Stem Cells



Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more

Not Available

Mechanism of action

All pMSCs contain therapeutic potential and have been used in medical treatment already as they are an ideal candidate for allogeneic transplantation due to their immunomodulatory properties and low immunogenicity. MSCs secrete growth factors and cytokines during angiogenesis, anti-fibrotic processes, chemotaxis, hematopoiesis induction, immunomodulation, and inhibition of apoptosis, with different levels of secretion between fetal- vs. maternal-side pMSCs. Fetal-side pMSCs secrete a higher level of HGF and VCAM-1 and hold potential in angiogenic therapy, while maternal-side pMSCs have the potential for treatment of critical limb ischemia as they secrete VEGF and Ang-1.


Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Not Available
Route of elimination

Not Available


Not Available


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more

Not Available

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


Drug Categories
Not Available
Not classified
Affected organisms
Not Available

Chemical Identifiers

CAS number
Not Available


General References
  1. Wu M, Zhang R, Zou Q, Chen Y, Zhou M, Li X, Ran R, Chen Q: Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord. Sci Rep. 2018 Mar 22;8(1):5014. doi: 10.1038/s41598-018-23396-1. [Article]
  2. Papait A, Vertua E, Magatti M, Ceccariglia S, De Munari S, Silini AR, Sheleg M, Ofir R, Parolini O: Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key Similarities and Differences: Potential Implications for Their Applications in Regenerative Medicine. Cells. 2020 Jan 6;9(1). pii: cells9010127. doi: 10.3390/cells9010127. [Article]
Not Available

Clinical Trials

Clinical Trials
3Active Not RecruitingTreatmentCritical Limb Ischemia (CLI)1
3Active Not RecruitingTreatmentHip Fracture1
2Active Not RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / COVID2
2CompletedTreatmentIntermittent Claudication / Peripheral Arterial Disease (PAD)1
1CompletedTreatmentCritical Limb Ischemia (CLI) / Peripheral Arterial Disease (PAD) / Peripheral Vascular Disease Patient2
1TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
1, 2CompletedTreatmentMuscle Injuries / Total Hip Arthroplasty (THA)1
1, 2RecruitingTreatmentMyelomeningocele1
Not AvailableActive Not RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19)1
Not AvailableAvailableNot AvailableCritical Limb Ischemia (CLI)2


Not Available
Not Available
Dosage Forms
Not Available
Not Available
Not Available


Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 19:12 / Updated at August 13, 2020 07:02